PEG-MGF
Pegylated Mechano Growth Factor | IGF-1 Splice Variant
On this page
What is PEG-MGF?
PEG-MGF is a modified version of a natural muscle-repair signal called MGF (a splice variant of IGF-1), with a chemical tag called PEG attached to make it last longer in the body. Researchers study how it activates dormant muscle stem cells (satellite cells) involved in tissue repair after mechanical stress or injury, mostly in cell and animal studies so far. It's sold here strictly as a research chemical for laboratory study, not for human or animal use.
Key terms:
PEG-MGF is a synthetic igf-1ec splice variant c-terminal peptide.
PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (IGF-1Ec), a splice variant of IGF-1. Polyethylene glycol is attached to extend its half-life from minutes to hours. Muscle tissue naturally expresses MGF after mechanical stress or injury. There it activates satellite cells, the repair cells of muscle. A landmark 2011 human cell study, cited 74+ times, found MGF significantly increased satellite cell proliferation at doses as low as 3ng/ml. Effects on proliferative lifespan appeared in cells from young donors but not elderly ones. In vitro and animal studies show promise for muscle regeneration, tissue repair, and neuroprotection. Human clinical research remains limited. PEG-MGF is not FDA-approved and is classified as a research chemical.
Key research areas
- Extended half-life (hours vs minutes for unmodified MGF) through PEGylation
- Activates satellite cells for muscle repair and regeneration
- May support recovery from mechanical stress or injury
Researched dosing
This table shows how researchers structure study designs with PEG-MGF, the dose ranges and post-workout timing used in research protocols, presented as methodology reference, not usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| General recovery protocols | 200mcg | 2-3 times weekly | Subcutaneous or intramuscular |
| Localized muscle-recovery studies | 200-400mcg | Post-workout, 2-3 times weekly | Intramuscular (bilateral, near target muscle) |
| Injury-recovery protocols | 200-400mcg | 2-3 times weekly | Intramuscular near injury site |
| Lower-dose study protocol | 100-200mcg | 2 times weekly | Subcutaneous |
Commonly cycled 8 weeks on, 4+ weeks off.
How it works
At the cell level, PEG-MGF research looks at how the peptide activates dormant muscle stem cells (satellite cells), triggering a signaling pathway involved in tissue repair, the terms below just name that process.
PEG-MGF activates muscle satellite (stem) cells by binding to specific receptors, stimulating the MAPK/ERK signaling pathway. This enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain appears to have distinct activity from mature IGF-1.
Molecular data
These figures, molecular weight, sequence, chain length, are the chemistry fingerprint researchers use to confirm a PEG-MGF sample's identity; the PEG attachment is what extends its activity from minutes to hours compared to unmodified MGF.
- Weight
- 2888 Da
- Length
- 24 amino acids
- Type
- IGF-1Ec splice variant C-terminal peptide
YQPPSTNNKNTKSQRRKGSTFEEHK
What the studies report
This section lists the body systems and research areas scientists have studied for PEG-MGF, mostly muscle-repair and tissue-regeneration research from cell and animal studies, summarizing what's been studied in the literature, not medical claims about people.
Muscle Repair
Primary mechanism - activates dormant muscle satellite cells, which fuse to damaged muscle fibers to aid repair and regeneration. Human cell studies show MGF E-peptide increases proliferative lifespan and delays senescence in muscle progenitor cells from younger donors. Research demonstrates increased fusion potential of activated satellite cells, supporting muscle fiber repair and potential hypertrophy.
Tissue Regeneration
MGF-24aa-E peptide was shown to favor in vivo migration of human myoblasts and improve human precursor cell transplantation outcomes, suggesting applications for cell-based therapies.
Recovery
Post-workout administration may align with natural MGF upregulation patterns, supporting overall recovery between training sessions.
Neuroprotection
Animal and in vitro studies show preliminary neuroprotective potential; human data remains limited.
Dosage reference
- Doses used in research
- 200-400 mcg per dose
- Frequency in studies
- 2-3 times weekly
- Handling
- Reconstituted solution, research use only; not for administration
- Timeline reported in studies
- Recovery benefits: 2-4 weeks. Optimal results: 6-8 weeks of consistent use
- Storage
- Lyophilized: room temperature stable. Reconstituted: refrigerate 2-8°C, use within 3-4 weeks
- Cycle length
- 4-8 weeks
- Break between cycles
- 4-8 weeks off between cycles to prevent receptor desensitization
Interactions
This list shows which other tissue-repair peptides are studied alongside PEG-MGF, and why.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried PEG-MGF powder into a liquid research solution, using an acetic-acid or bacteriostatic-water diluent for stability.
- Allow vial to reach room temperature
- Clean rubber stopper with alcohol swab
- Draw appropriate amount of acetic acid or BAC water (e.g., 2mL for 1mg/mL concentration)
- Inject slowly along vial wall, not directly onto powder
- Gently swirl to dissolve - never shake
- Allow to fully dissolve (2-5 minutes)
- Protect from light - acetic acid provides longer stability than BAC water
Lyophilized: Room temperature stable, use within Per manufacturer expiration date
Reconstituted: 2-6°C, use within 3-4 weeks
Open the PEG-MGF reconstitution calculatorQuality indicators
These are the visual and lab-report checks researchers use to confirm a PEG-MGF sample is pure and correctly identified, a quick sanity check against the Certificate of Analysis (COA), not a guarantee.
White Lyophilized Powder - Should appear as a white or off-white fluffy cake at the bottom of the vial. Indicates proper freeze-drying.
Clear After Reconstitution - When mixed with bacteriostatic water, solution should be crystal clear with no particles or cloudiness.
Minor Clumping Acceptable - Small clumps that dissolve completely with gentle swirling are normal. Shipping can cause minor compaction.
Collapsed or Discolored - If powder appears collapsed, yellowed, or stuck to vial sides, it may be degraded from heat exposure.
Cloudy or Particles - Persistent cloudiness or visible particles after reconstitution indicate contamination or degradation - do not use.
Certificate of Analysis - Reputable suppliers provide HPLC purity testing (>98%) and mass spectrometry verification. Always request COA.
What to expect
This timeline summarizes what the available research literature reports at each stage of a study, research context for comparing studies, not a personal-results promise.
Reported early effects include reduced muscle soreness after exercise and subtle recovery improvements
Reported improvements in recovery between training sessions and reduced injury-related discomfort
Peak reported effects on muscle-repair endpoints, with improved training capacity attributed to recovery
Effects were reported to persist for several weeks as tissue-repair processes continued
Safety notes
This section covers handling and regulatory notes for PEG-MGF, research-use-only scope, including a caution around any history of neoplastic disease given its growth-factor-related mechanism.
- Not FDA-approved - research chemical only with limited human safety data
- Contraindicated with any history of cancer or neoplastic disease
- Discontinue if any unusual growths, lumps, or tissue changes occur
- Long-term safety profile is unknown
- May affect blood glucose - monitor if diabetic or pre-diabetic
- Not recommended during pregnancy or breastfeeding
- Age-dependent response: in the human cell study, the longer proliferative life span and the delayed senescence appeared in cells from newborn and young adult donors and not in cells from old adult donors. The increase in fusion was reported in cultures from every age group
- May deplete reserve cell population - hypertrophy was associated with decreased reserve cells in studies
- Not FDA-approved - research chemical only
- Prohibited in competitive sports (WADA banned substance)
Regulatory status
- Not approved by the FDA for any indication.
- Prohibited by the World Anti-Doping Agency (WADA).
- Supplied and described for laboratory research use only, not for human or veterinary use.
What is not known
The limits of the published work on PEG-MGF, stated plainly. Research use only: none of this is guidance for a person.
The landmark human study is a cell culture study. Cells in a dish are not a body, no trial in people has been published, and what it does in a person is not known.
Its two findings are often merged into one. The longer proliferative life span appeared only in cells from young donors. The increase in fusion appeared at every age. A page that reports one as if it were the other is reporting the paper backwards.
The animal work is on MGF itself, mostly through gene overexpression. It says nothing about the PEG modified peptide sold as a research chemical.
There is no published pharmacokinetic study of PEG-MGF in people, so the extended activity quoted for it is read off the PEG chemistry and is not measured.
What long exposure to a growth signal does is not known, which is the reason the safety notes on this page are cautious.
The terms, in plain words
Every technical term this page leans on, said again in ordinary words.
- Satellite cells
- Dormant repair cells that sit alongside muscle fibres and wake up when the muscle is damaged.
- Splice variant
- A different version of a protein made by reading the same gene a different way.
- PEGylation
- Attaching a chain of polyethylene glycol to a molecule so the body clears it more slowly.
- Senescence
- The state a cell reaches when it stops dividing for good.
- Fusion
- When repair cells merge into an existing muscle fibre, which is how they add to it.
- Proliferative life span
- How many times a cell can still divide before it stops.
Sources
The published work behind this entry. Each link was opened and each note says what that paper reports, not what it suggests.
- Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages Mechanisms of Ageing and Development, 2011Human muscle cell cultures from donors of different ages. The source of both age findings on this page, and the reason they have to be stated separately.
How it is studied
In the published studies listed below. Each one names the species it was run in, the dose, how long it ran, and what it reported.
MGF overexpression modulated inflammatory cytokine expression and enhanced macrophage resolution during skeletal muscle injury recovery. Suggests MGF plays role in coordinating inflammatory-to-regenerative phase transition.
Human muscle cell cultures from donors of different ages. The MGF E peptide increased the proliferative life span and delayed senescence in cells from newborn and young adult donors, and not in cells from old adult donors. An increase in fusion was reported in cultures from every age group. The authors propose it as a route to work on age related muscle loss without the cancer-related concerns raised for IGF-1.
View StudyMGF-24aa-E peptide was shown to favor in vivo migration of human myoblasts and improve human precursor cell transplantation outcomes, suggesting applications for cell-based therapies.